[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"aneurysmal-subarachnoid-hemorrhage-asah\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:aneurysmal-subarachnoid-hemorrhage-asah":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,50,80,104,127,148,180],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":30,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":49},"100642201","phase-4-early-prophylactic-aspirin-for-aneurysmal-subarachnoid-hemorrhage-100642201",false,"NCT07642427","Early Prophylactic Aspirin for Aneurysmal Subarachnoid Hemorrhage","Study on the Efficacy and Safety of Early Prophylactic Use of Aspirin in Improving Prognosis of Patients With Aneurysmal Subarachnoid Hemorrhage: A Multicenter, Prospective, Double-Blind, Randomized Controlled Trial","aSAH-ASA","Inclusion Criteria:\n\n1. Age ≥ 18 years and ≤ 80 years.\n2. Spontaneous subarachnoid hemorrhage (SAH) confirmed by non-contrast head CT.\n3. Diagnosis of ruptured intracranial aneurysm confirmed, and successfully treated by either surgical clipping or endovascular coiling within 48 hours of ictus.\n4. Hunt-Hess grade ≤ 4 or WFNS grade ≤ 4 (assessed within 48 hours of SAH onset).\n5. Fisher grade 2-4 or modified Fisher grade 1-4.\n6. No significant focal neurological deficit after aneurysm intervention, defined as NIHSS scores ≤ 1 in the following items: 5a (left arm motor), 5b (right arm motor), 6a (left leg motor), 6b (right leg motor), and 9 (language).\n7. Pre-morbid modified Rankin Scale (mRS) score ≤ 1 prior to SAH onset.\n\nExclusion Criteria:\n\n1. Hunt-Hess grade 5 or WFNS grade 5 (assessed within 48 hours of SAH onset).\n2. Patients requiring any intracranial stent or non-embolic intrasaccular device during aneurysm embolization, with post-procedural need for antiplatelet therapy.\n3. Angiogram-negative SAH.\n4. Note: Prior history of ruptured intracranial aneurysm or re-rupture of previously treated aneurysm is not excluded.\n5. Moderate-to-severe vasospasm demonstrated on pre-operative or intra-operative CTA\u002FDSA in the emergency setting.\n6. SAH caused by non-saccular aneurysms, including mycotic, blood-blister, fusiform, or dissecting aneurysms, or cases without basal cistern subarachnoid hemorrhage.\n7. Significant pre-existing intracranial pathology at the time of enrollment, including but not limited to: traumatic brain injury, moyamoya disease, high suspicion or documented CNS vasculitis, severe fibromuscular dysplasia, arteriovenous malformation, arteriovenous fistula, significant cervical or intracranial atherosclerotic stenosis (≥70%), or malignant brain tumor.\n8. Medical conditions requiring chronic use of antiplatelet agents (aspirin, clopidogrel, or ticagrelor), such as transient ischemic attack, myocardial infarction, atrial fibrillation, prosthetic heart valve, arteriovenous fistula, unstable angina, or other conditions requiring thromboprophylaxis.\n9. Thrombocytopenia (platelet count \\\u003C20,000\u002FμL, excluding aggregation artifacts), active disseminated intravascular coagulation (DIC) at enrollment, or documented history of coagulopathy or bleeding diathesis.\n10. History of gastrointestinal bleeding or major systemic hemorrhage within 30 days, hemoglobin \\\u003C8 g\u002FdL at admission, INR ≥1.5, or severe hepatic impairment defined as AST, ALT, alkaline phosphatase (AP), or GGT \\>2 times the upper limit of normal.\n11. Creatinine clearance \\\u003C30 mL\u002Fmin.\n12. Severe comorbidities that may confound study outcomes, including but not limited to: multiple sclerosis, dementia, major depression, immunosuppressed state or during intensive immunosuppressive therapy, cancer with expected survival \\\u003C1 year, multi-organ failure, or any other condition potentially causing cognitive impairment.\n13. Contraindications to aspirin therapy, including:\n\n    * Hypersensitivity to aspirin, other salicylates, or any excipients in the formulation;\n    * History of asthma induced by salicylates or NSAIDs;\n    * Active peptic ulcer disease;\n    * Bleeding diathesis;\n    * Hepatic or renal failure;\n    * Uncontrolled severe heart failure;\n    * Concomitant use with methotrexate at doses ≥15 mg\u002Fweek.\n14. Pregnancy or positive HCG test.\n15. Incomplete repair of the responsible aneurysm as judged by the treating physician, with high risk of early re-bleeding.\n16. History of head trauma within 3 months prior to SAH onset.\n17. Recent cerebral disease within 3 months prior to SAH onset, such as tumor, stroke, epilepsy, vasculitis, AVM, or hydrocephalus.\n18. History of psychiatric illness or seizure disorder.\n19. Breastfeeding women.\n20. Expected survival \\\u003C1 year prior to SAH onset.\n21. Participation in another randomized clinical trial that may confound the evaluation of this study.","ALL","18 Years","80 Years",{"count":21,"type":22},388,"ESTIMATED","INTERVENTIONAL",[25],"PHASE4","This study is a multicenter, prospective, double-blind, randomized controlled trial designed to evaluate whether early prophylactic use of aspirin improves functional outcomes in patients with aneurysmal subarachnoid hemorrhage (aSAH). Patients with aSAH who have undergone successful aneurysm securing will be randomly assigned to receive either aspirin plus standard care or a placebo plus standard care. The study drug will be started within 48 hours of undergone successful aneurysm securing and continued for not less than 10 days and not more than 14 consecutive days. The main goal is to compare the rate of favorable functional outcomes at 3 months between the two groups. Secondary goals include evaluating the incidence of delayed cerebral ischemia, cerebral infarction, mortality, and safety outcomes such as major bleeding events.",[28,29],"Aneurysmal Subarachnoid Hemorrhage (aSAH)","Delayed Cerebral Ischemia",[31,32,33,34,35,36],"Aneurysmal subarachnoid hemorrhage","Aspirin","Delayed cerebral ischemia","Antiplatelet therapy","Functional outcome","Randomized controlled trial","NOT_YET_RECRUITING","2026-06-07",{"date":40,"type":41},"2026-06-11","ACTUAL",{"date":43,"type":22},"2026-06-01",{"date":45,"type":22},"2029-08",{"name":47,"class":48},"Ganzhou City People's Hospital","OTHER",1,{"id":51,"slug":52,"hasResults":11,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":56,"eligibilityCriteria":57,"healthyVolunteers":11,"sex":17,"minAge":58,"maxAge":4,"enrollmentInfo":59,"targetDuration":61,"studyType":62,"phases":4,"briefSummary":63,"conditions":64,"keywords":66,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":79},"100584763","registry-on-neva-vs-for-cerebral-vasospasm-management-in-post-sah-patients-100584763","NCT06893588","Registry on NeVa VS for CerebraL VAsospasm ManagemenT in Post SAH PatiEnts","Prospective, Open-Label, Multi-Center ProceDural Data CollectIon Case Registry on NeVa VS for CerebraL VAsospasm ManagemenT in Post SAH PatiEnts (The DILATE Registry)","DILATE","Inclusion Criteria:\n\n1. Age ≥22\n2. Symptomatic cerebral vasospasm secondary to aneurysmal subarachnoid hemorrhage (aSAH) in the internal carotid artery (ICA), middle cerebral artery (MCA), anterior cerebral artery (ACA), posterior cerebral artery (PCA), or basilar artery (BA)\n3. Vessel dilation procedure was performed with the NeVa VS\n4. Subject or legal representative is able and willing to give informed consent within 3 days (72 hours) post-index procedure\n\nExclusion Criteria:\n\n* None","22 Years",{"count":60,"type":22},200,"30 Days","OBSERVATIONAL","A multi-center, observational registry study intended to assess the HDE-approved NeVa VS cerebral artery dilation device in patients with symptomatic cerebral vasospasm caused by aneurysmal subarachnoid hemorrhage (aSAH)",[65,28],"Cerebral Vasospasm",[67],"vasospasm","RECRUITING","2026-05-23",{"date":71,"type":41},"2026-05-27",{"date":73,"type":41},"2025-04-14",{"date":75,"type":22},"2027-03-15",{"name":77,"class":78},"Vesalio","INDUSTRY",16,{"id":81,"slug":82,"hasResults":11,"nctId":83,"briefTitle":84,"officialTitle":85,"acronym":4,"eligibilityCriteria":86,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":87,"targetDuration":4,"studyType":23,"phases":89,"briefSummary":90,"conditions":91,"keywords":93,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":102,"locationsCount":49},"100601892","phase-4-intranasal-sphenopalatine-ganglion-blockade-for-headaches-following-aneurysmal-subarachnoid-hemorrhage-100601892","NCT07116408","Intranasal Sphenopalatine Ganglion Blockade for Headaches Following Aneurysmal Subarachnoid Hemorrhage","Intranasal Sphenopalatine Ganglion Blockade as a Non-invasive, Opioid-sparing Treatment for Headaches Following Aneurysmal Subarachnoid Hemorrhage","Inclusion Criteria:\n\n• Patients aged 18 years or older who are being treated in the neurologic ICU for subarachnoid hemorrhage with Hunt and Hess scale of 0-3 (Scale ranges from 0 to 5 with higher numbers indicating more severe symptoms) and able to verbally report headache will be considered for inclusion in this study.\n\nExclusion Criteria:\n\n* Patients under the age of 18 years of age.\n* Patients with an allergy to lidocaine.\n* Patients from all vulnerable groups.\n* Patients with Hunt and Hess scale score of 4-5. (Scale ranges from 0 to 5 with higher numbers indicating more severe symptoms.)\n* Patients who are not able to consent.\n* Mentally impaired patients that are unable to provide consent.\n* Patients that are prisoners.\n* Pregnant patients.\n\nAdditionally, patients with contraindications to use of the Tx 360 device will be excluded. Contraindications include:\n\n* History of recurrent nose bleeds.\n* Nasal septal deformity such as cleft lip and palate, choanal atresia (narrowed nasal passages), atrophic rhinitis, rhinitis medicamentosa, septal perforation, nasal\u002Fmidface trauma.\n* Recent nasal\u002Fsinus surgery\n* Presence of a bleeding disorder (eg., Von Willebrand's disease or hemophilia).\n* Severe respiratory distress.\n* Presence of angiofibroma, sinus tumor, or granulomatous disease of the nasopharynx.\n* Presence of nasal trauma.\n* Nasal congestion that has been present more than 10 days, high fever, or abnormal appearance of the nasal mucosa or mucus.",{"count":88,"type":22},20,[25],"In patients with bleeding from a brain aneurysm, severe headache is the most common complaint. However, the pain is difficult to treat. The use of standard pain medications is common, but pain control remains poor. Additionally, pain medicines have multiple side effects including sedation, interference with breathing, intestinal cramping, low blood pressure, and the risk of addiction. In the present study, the investigators will examine the use of a medication to block the sphenopalatine ganglion which is a bundle of nerves that includes nerves that cause head pain. This block is performed by spraying numbing medication into the back of the nasal cavity on both sides. This particular pain medication does not have the side effects discussed above. The purpose of the study is to see if this treatment will decrease pain without causing unwanted side effects.\n\nAll patients in the study will receive standard pain medicine as needed for headache. Information will be collected from the patient's medical chart on the amount of pain medication used and the amount of pain the patient describes having. The average pain will be calculated for the first 24 hours the patient is in the hospital. At that point, the patient will receive pain medication sprayed into the back of the nasal cavity on both sides. Patients will also receive this treatment 3 days later. Following these treatments, information will be obtained on the average amount of pain, and how much other pain medication is used.\n\nThe investigators will look at the amount of pain and the amount of other pain medicine used over the first 24 hours before the nasal pain medicine treatment and compare it to the time after the treatments to see if the amount of pain decreases and if the amount of other pain medicine needed decreases as well. Six months after discharge, the patient will be contacted by phone to find out more information about how much head pain they had after discharge from the hospital.",[28,92],"Headache",[92,94,95],"subarachnoid hemorrhage","aneurysm","2026-05-21",{"date":71,"type":41},{"date":99,"type":41},"2024-05-20",{"date":101,"type":22},"2027-05",{"name":103,"class":48},"Wright State University",{"id":105,"slug":106,"hasResults":11,"nctId":107,"briefTitle":108,"officialTitle":109,"acronym":4,"eligibilityCriteria":110,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":111,"targetDuration":113,"studyType":62,"phases":4,"briefSummary":114,"conditions":115,"keywords":116,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":118,"lastUpdatePostDateStruct":119,"startDateStruct":121,"completionDateStruct":123,"leadSponsor":125,"locationsCount":49},"100619331","correcting-hypocapnia-in-aneurysmal-subarachnoid-hemorrhage-100619331","NCT07343232","Correcting Hypocapnia in Aneurysmal Subarachnoid Hemorrhage.","Safety and Efficacy of Normobaric Facemask Oxygen for Hypocapnia in Aneurysmal Subarachnoid Hemorrhage(FOCAL): A Prospective, Multicenter, Proof-of-concept Pilot Study","Inclusion Criteria:\n\n1. Age \\> 18 years.\n2. Confirmed diagnosis of aneurysmal subarachnoid hemorrhage (aSAH), with the presence of an aneurysm verified by computed tomography (CT), CT angiography (CTA), or digital subtraction angiography (DSA).\n3. Hunt-Hess grade II-IV.\n4. Presence of hypocapnia on arterial blood gas analysis, defined as PaCO2 \\\u003C 35 mmH;\n5. PaO2 \\> 90 mmHg.\n\nExclusion Criteria:\n\n1. Presence of brain herniation or refractory intracranial hypertension, defined as a baseline intracranial pressure (ICP) \\> 25 mmHg that responds poorly to conventional ICP-lowering therapy;\n2. Primary respiratory diseases (e.g., chronic obstructive pulmonary disease, severe asthma) known to cause chronically elevated baseline PaCO2;\n3. Severe acid-base disturbances other than respiratory alkalosis.\n4. Severe cardiac insufficiency, severe hepatic or renal dysfunction, malignant tumors, or other severe comorbidities that significantly impact prognosis;\n5. Before the onset of the disease, the mRS score was greater than 2, and there were other factors causing disability.\n6. Life expectancy \\\u003C 3 months;\n7. Any other condition deemed by the investigator to pose a high risk warranting exclusion.",{"count":112,"type":22},80,"90 Days","Based on the clinical observation that over half of the patients in the management of aneurysmal subarachnoid hemorrhage(aSAH) present with spontaneous hyperventilation, which is significantly associated with delayed cerebral ischemia and poor neurological outcomes, this prospective pilot study is designed to investigate the safety and efficacy of normobaric facemask oxygen for hypocapnia in aSAH.",[28],[28,117],"Hypocapnia","2026-01-06",{"date":120,"type":41},"2026-01-15",{"date":122,"type":22},"2026-01-01",{"date":124,"type":22},"2026-10-30",{"name":126,"class":48},"The Chinese University of Hong Kong, Shenzhen",{"id":128,"slug":129,"hasResults":11,"nctId":130,"briefTitle":131,"officialTitle":132,"acronym":4,"eligibilityCriteria":133,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":134,"enrollmentInfo":135,"targetDuration":4,"studyType":62,"phases":4,"briefSummary":137,"conditions":138,"keywords":4,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":139,"lastUpdatePostDateStruct":140,"startDateStruct":142,"completionDateStruct":144,"leadSponsor":146,"locationsCount":49},"100605251","dind-in-patients-with-asah--real-world-study-100605251","NCT07160088","DIND in Patients With aSAH : Real World Study","Delayed Ischemic Neurological Deficit in Patients With Aneurysmal Subarachnoid Hemorrhage: Real World Study (DINDaSAH)","Inclusion Criteria:\n\n1. Age ≥ 18 years old\n2. Primary diagnosis of subarachnoid hemorrhage due to rupture of a cerebral artery aneurysm confirmed by cerebral angiotomography or intracranial vessel angiography, requiring admission to the Intensive Care Unit (ICU).\n3. Signature of the Informed Consent Form for participation in the study in accordance with local applicable regulations.\n\nExclusion Criteria:\n\n1. Age \\\u003C 18 years old\n2. Primary diagnosis of subarachnoid hemorrhage withouth a visible aneurysm, i.e., post-traumatic or caused by an arteriovenous malformation or bleeding from a brain tumor.","90 Years",{"count":136,"type":22},10000,"In recent years, with the active application of clinical monitoring and treatment methods, the survival rate of patients with aneurysmal subarachnoid hemorrhage (SAH) has improved, but still a certain proportion of patients develop chronic and disabling neurological deficits, namely delayed ischemic neurological deficits (DIND). The incidence of DIND is not clear, and the causes are diverse. Symptomatic vasospasm is only one of the possible causes, and early diagnosis is difficult. Up to now, there is no gold standard for diagnosis and no relevant treatment guidelines.\n\nGiven these reasons, this study intends to conduct a prospective multicenter observational study to collect relevant information on diagnostic methods (neurological symptoms in clinical examinations or changes in monitoring by instruments) and treatment methods, describe the incidence of delayed cerebral ischemia (DIND) in patients with subarachnoid hemorrhage (SAH), evaluate the different treatment strategies adopted by participating centers, and compare these strategies in terms of mortality and short-term and long-term neurological outcomes, and describe the indications, usefulness, and treatment intensity of intracranial pressure monitoring of the brain parenchyma during SAH in patients.\n\nStudy design: This study is a multicenter, prospective, observational study. The study subjects are patients with subarachnoid hemorrhage as the primary diagnosis, admitted to the intensive care unit and receiving treatment. The treatment of patients with subarachnoid hemorrhage (SAH) and delayed cerebral ischemia (DIND) is the responsibility of the professional medical and surgical teams of each center.\n\nStudy period: The enrollment period is 12 months from the start of ethical approval, and the follow-up period is 12 months after the onset.\n\nInclusion criteria:\n\n① Age ≥ 18 years; ② Aneurysmal subarachnoid hemorrhage (confirmed by DSA\u002FCTA); ③ Admitted to the intensive care unit; ④ Signed informed consent.\n\nExclusion criteria:\n\n① Unidentified cause of subarachnoid hemorrhage (no visible aneurysm); ② Traumatic SAH; ③ Complicated with brain tumors or arteriovenous malformations.\n\nEndpoints:\n\nPrimary endpoints: The occurrence of suspected DIND: Whether it is indicated by neurological clinical examination (such as the patient being conscious or in a light sedated state), or by the monitoring of instruments (if clinical examination is impossible), suggesting the possibility of DIND, regardless of whether there is imaging confirmation or not, can be considered as suspected DIND.\n\nSecondly endpoints: - The clinical application of diagnostic and monitoring methods in the identification and management of DIND in patients with aSAH.\n\n* Evaluation of mortality and neurological functional prognosis (GOSE and mRS) at 6 months and 12 months after onset.\n* Comparison of changes in intracranial pressure (ICP) in patients with ICP monitoring and the intensity of the treatment received (Therapy Intensity Level, TIL).\n\nSample size:\n\nThe enrollment will be as much as possible during the enrollment period (totally approximately 1000 cases).",[28],"2025-12-28",{"date":141,"type":41},"2026-01-02",{"date":143,"type":41},"2025-09-03",{"date":145,"type":22},"2027-12-31",{"name":147,"class":48},"Xuanwu Hospital, Beijing",{"id":149,"slug":150,"hasResults":11,"nctId":151,"briefTitle":152,"officialTitle":152,"acronym":153,"eligibilityCriteria":154,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":155,"targetDuration":4,"studyType":23,"phases":157,"briefSummary":159,"conditions":160,"keywords":162,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":171,"lastUpdatePostDateStruct":172,"startDateStruct":174,"completionDateStruct":176,"leadSponsor":178,"locationsCount":49},"100616584","efficacy-of-scalp-block-in-managing-post-subarachnoid-hemorrhage-headache-in-critically-ill-patients-a-single-centre-randomized-controlled-trial-100616584","NCT07307508","Efficacy of Scalp Block in Managing Post Subarachnoid Hemorrhage Headache in Critically Ill Patients. A Single Centre Randomized Controlled Trial","SAH-BLOCK","Inclusion Criteria:\n\n* All adults \\> 18 years who are admitted to the Surgical Intensive Care Unit (SICU) with a confirmed diagnosis of aneurysmal subarachnoid hemorrhage, undergoing endovascular treatment of the aneurysm (coiling\u002Fflow diversion).\n\nExclusion Criteria:\n\n1. Patients with aSAH undergoing surgical craniotomy and aneurysmal clipping.\n2. Non-aneurysmal subarachnoid or other intracranial hemorrhage forms (e.g., Intracerebral hemorrhage).\n3. SICU admission Glasgow Coma Scale (GCS) of 13 or lower.\n4. WFNS Score 4 \u002F 5 or requiring mechanical ventilation for more than 24 hrs.\n5. Patients with known allergy to local anesthetics.\n6. Admission to ICU \\> 7 days after hemorrhage.\n7. Patients with a documented bleeding disorder.\n8. Patients with a history of chronic headache disorder or migraine.\n9. Pregnancy",{"count":156,"type":22},22,[158],"NA","Subarachnoid hemorrhage (SAH) is a devastating neurological disorder associated with significant mortality and morbidity rates, arising not just from the hemorrhage itself but also because of the catastrophic multisystem sequelae that can accompany the condition.\n\nRupture of an intracranial aneurysm accounts for up to 85% of instances of SAH, occurring in approximately 3 to 25 people per 100,000 annually in most populations. Treatment of aneurysmal SAH (aSAH) includes prevention of re-bleeding, evacuation of space-occupying hematomas, management of hydrocephalus, and prevention of secondary cerebral insult. Severe headache is the predominant characteristic symptom of aSAH, developing almost instantaneously at ictus in 50% of cases and continuing into the first days. Its severity has a variety of physiological and psychological effects on the patient. Scalp blocks have been suggested to alleviate this headache in case series. However, there is no strong evidence supporting this intervention. In this study, we aim to assess the impact of scalp blocks on headache reduction in patients undergoing endovascular treatment of an aneurysm (coiling or flow diversion) with aneurysmal subarachnoid bleeding.",[28,161],"Headache Disorders",[163,164,165,166,167,168,169,170],"Subarachnoid Hemorrhage Headache","Aneurysmal Subarachnoid Hemorrhage","Cerebral Aneurysm","SAH-associated headache","Scalp Block","Levobupivacaine","Opioid Consumption","Neurocritical Care","2025-12-14",{"date":173,"type":41},"2025-12-29",{"date":175,"type":41},"2025-10-22",{"date":177,"type":22},"2026-12-30",{"name":179,"class":78},"Hamad Medical Corporation",{"id":181,"slug":182,"hasResults":11,"nctId":183,"briefTitle":184,"officialTitle":184,"acronym":185,"eligibilityCriteria":186,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":187,"enrollmentInfo":188,"targetDuration":4,"studyType":23,"phases":190,"briefSummary":191,"conditions":192,"keywords":193,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":198,"lastUpdatePostDateStruct":199,"startDateStruct":201,"completionDateStruct":203,"leadSponsor":205,"locationsCount":49},"100604469","early-blood-pressure-intervention-after-coiling-or-clipping-for-subarachnoid-hemorrhage-100604469","NCT07149922","Early Blood Pressure Intervention After Coiling or Clipping for Subarachnoid Hemorrhage","EPIC-SAH","Inclusion Criteria:\n\n* 1\\) Aged 18-75 years;\n\n  2\\) Patients who underwent clipping or endovascular intervention within 72 hours post-ictus;\n\n  3\\) Intracranial aneurysm diagnosis confirmed by operating surgeons (including neurosurgeons or neurointerventionalists) through imaging findings, intraoperative visualization, or angiography, with subarachnoid hemorrhage (SAH) attributable to the ruptured aneurysm lesion (verified via imaging, xanthochromic cerebrospinal fluid, or intraoperative observation);\n\n  4\\) Hunt-Hess grade 1-4 at onset;\n\nExclusion Criteria:\n\n* 1\\) Presence of untreated intracranial aneurysms with rupture risk;\n\n  2\\) Moderate-to-severe cerebral vasospasm confirmed by pre-enrollment digital subtraction angiography (DSA), transcranial Doppler (TCD), or computed tomography angiography (CTA);\n\n  3\\) Intracranial massive hematoma (e.g., volume \\>30 mL with midline shift \\>5 mm) causing severe cerebral herniation, as evidenced by admission CT or other imaging modalities;\n\n  4\\) Prior cranial neurosurgery for other central nervous system disorders;\n\n  5\\) Comorbid major systemic diseases or multi-organ dysfunction with life expectancy \\\u003C1 year, potentially compromising study implementation or follow-up observations;\n\n  6\\) Poorly controlled hypertension despite regular antihypertensive medication (e.g., systolic blood pressure \\>160 mmHg during pharmacotherapy);\n\n  7\\) Pre-onset modified Rankin Scale (mRS) score \\>2 points, indicating disability from other causes;\n\n  8\\) Intraoperative major complications including but not limited to massive cerebral hemorrhage, hypovolemic shock, or malignant brain swelling;\n\n  9\\) Anticipated inability to complete scheduled follow-up assessments within 180 days;\n\n  10\\) Pregnancy.","75 Years",{"count":189,"type":22},750,[158],"The goal of this clinical trial is to learn if elevating postoperative blood pressure works to improve prognosis in aneurysmal subarachnoid hemorrhage (aSAH) patients. The main questions it aims to answer are:\n\nDoes elevating postoperative blood pressure can improve the prognosis of aSAH ? What safety problems do participants have when received elevating blood pressure measurement?\n\nParticipants will:\n\nReceive elevating or lowering blood pressure therapy in 72 hours after randomization, in order to maintain blood pressure within predefined target ranges Receive follow-up at 30 days, 90 days, and 180 days after randomization",[164,28],[194,195,196,197],"aneurysmal subarachnoid hemorrhage","delayed cerebral ischemia","blood pressure","prognosis","2025-08-24",{"date":200,"type":41},"2025-09-02",{"date":202,"type":22},"2025-08-31",{"date":204,"type":22},"2028-07-31",{"name":206,"class":48},"Beijing Tiantan Hospital"]